

Dapoflit MV Tablet

Brand Name: Dapoflit MV Tablet

Dosage Form: Tablet

Composition:

Each film-coated tablet contains:

- Dapagliflozin IP 10 mg
- Metformin Hydrochloride IP 1000 mg
- Vildagliptin IP 100 mg

Description:

Dapoflit MV Tablet is a fixed-dose combination of Dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, Metformin Hydrochloride, a biguanide, and Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is indicated for the management of type 2 diabetes mellitus when adequate glycemic control is not achieved with dual therapy. It helps in improving glycemic control through complementary mechanisms of action.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on dual antidiabetic therapy

It helps in controlling fasting and post-prandial blood glucose levels and improving overall glycemic parameters.

Dosage & Administration:

Dosage should be as directed by the physician.

The tablet should be swallowed whole with water and preferably taken with meals.

Regular monitoring of blood glucose and renal function is recommended.

Pharmacological Action:

Dapagliflozin reduces renal glucose reabsorption by inhibiting SGLT2, leading to increased urinary glucose excretion. Metformin decreases hepatic gluconeogenesis, improves insulin sensitivity, and reduces intestinal glucose absorption. Vildagliptin inhibits DPP-4, increasing incretin hormone levels that enhance glucose-dependent insulin secretion and suppress glucagon release.

Side Effects:

Generally well tolerated.

Possible side effects include gastrointestinal disturbances, headache, dizziness, increased urination, urinary tract infections, genital infections, and hypoglycemia when used with other antidiabetic agents.

Precautions & Warnings:

- Use with caution in patients with renal or hepatic impairment

- Assess renal function before initiation and periodically thereafter
- Risk of lactic acidosis associated with metformin in predisposed patients
- Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

Drug Interactions:

Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia.
Alcohol intake may increase the risk of lactic acidosis.

Storage:

Store below 25°C in a cool, dry place.

Protect from light and moisture.

Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for